Navigation Links
NeurogesX to Hold Conference Call to Discuss Third Quarter 2010 Results
Date:10/28/2010

s and uncertainties, including, but not limited to: difficulties or delays in the submission of the supplemental NDA for Qutenza; data submitted may not be sufficient to support FDA approval of Qutenza in the treatment of pain associated with HIV-AN; market acceptance of Qutenza in already approved indications may not be sufficient to support further pursuit of an expanded label for Qutenza, including as a result of physician or patient reluctance to use Qutenza; Qutenza and NeurogesX' other product candidates may have unexpected adverse side effects; and potential alternative therapies. For further information regarding these and other risks related to NeurogesX's business, investors should consult NeurogesX's filings with the Securities and Exchange Commission. NeurogesX, Inc.The Ruth GroupStephen Ghiglieri

Sara Pellegrino (investors)Executive Vice President, COO

(646) 536-7002and CFO

spellegrino@theruthgroup.com(650) 358-3310Jason Rando (media)(646) 536-7025jrando@theruthgroup.com
'/>"/>

SOURCE NeurogesX
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
4. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
5. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
6. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
7. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
8. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
9. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
10. NeurogesX to Present at JMP Securities Healthcare Focus Conference
11. NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- ReportsnReports.com adds Global Medical Simulation ... as well as Global Medical Simulation Market 2015-2019 ... of its library. Complete 2015 report ... across 164 pages, talking about 7 major companies ... now available at http://www.reportsnreports.com/reports/407046-global-medical-simulation-industry-report-2015.html . ...
(Date:8/3/2015)... , Aug. 3, 2015  Depomed, Inc. (NASDAQ: ... Horizon Pharma plc,s (NASDAQ: HZNP ) ("Horizon") announcement ... Directors ("Depomed Board") set a record date to determine ... The Depomed Board will review the request ... received today and contains the information required under Depomed,s ...
(Date:8/3/2015)... Va. , Aug. 3, 2015  Dr. ... joining Orthopaedic & Spine Center today, ... to manage their chronic pain through psychological counseling ... is a Fellowship-trained, certified medical psychologist with ... medicine. His vast experience ranges from assessment and ...
Breaking Medicine Technology:Medical Simulation Market to see 14% CAGR to 2019 2Medical Simulation Market to see 14% CAGR to 2019 3Medical Simulation Market to see 14% CAGR to 2019 4Medical Simulation Market to see 14% CAGR to 2019 5Medical Simulation Market to see 14% CAGR to 2019 6Depomed Comments on Horizon Pharma Announcement 2Depomed Comments on Horizon Pharma Announcement 3Depomed Comments on Horizon Pharma Announcement 4Depomed Comments on Horizon Pharma Announcement 5Depomed Comments on Horizon Pharma Announcement 6Orthopaedic & Spine Center Introduces New Pain Psychologist 2
... Diagnostics Incorporated (NYSE: DGX ), the world,s leading ... its Board of Directors declared a quarterly cash dividend of ... of record of Quest Diagnostics common stock on April 3, ... Quest Diagnostics is the world,s leading provider of diagnostic testing, ...
... 28, 2012 HistoRx, the leader in quantitative ... technology and critical elements of digital microscopy standardization.  ... the US Patent & Trademark Office advance the ... pathology to a dominant role in the industry.  ...
Cached Medicine Technology:HistoRx Achieves Dominant Intellectual Property Position in Standardization of Results from Digital Pathology Instruments 2HistoRx Achieves Dominant Intellectual Property Position in Standardization of Results from Digital Pathology Instruments 3
(Date:8/3/2015)... ... August 03, 2015 , ... They know every second counts. And when it ... offers some of the best care in the nation. For the past two months, ... average blood clot removal time in the country. During the months of June and ...
(Date:8/3/2015)... Angeles, California (PRWEB) , ... August 03, 2015 ... ... Fifth Circuit Court of Appeals ruled in favor of the firm’s client Rebecca ... ), North Cypress Medical Center must reimburse benefits for Hamsher’s residential treatment for ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... researchers from the University of Pittsburgh School of Medicine are leading a five-year, ... drugs in sub-Saharan Africa. , A cooperative agreement awarded by the U.S. ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, the nation’s largest healthcare ... lab testing and precision medicine solutions that can help pharmacists and other healthcare ... than 8.6 million adverse drug events are reported in the U.S. Pharmacogenetic ...
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent Pharma ... drugs, biologics and consumer health products, today welcomed the announcement by OPKO Health ... Drug Application for a new treatment for chronic kidney disease (CKD) and vitamin ...
Breaking Medicine News(10 mins):Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3
... 3, 2011) A drug that targets a specific ... than half of the people who take it. The drug, ... the results from the largest group of patients to take ... presented at the annual meeting of the American Society of ...
... of Allergy and Infectious Diseases (NIAID), part of the National ... exposed to HIV shut down, and how they can be ... of surface proteins that the immune system can use, like ... activate the cell or to damp down its activity. However, ...
... research study investigates the challenges that pen and ... the use of electronic health records. Understanding these ... supported by health IT. Focusing on referrals ... from the specialists back to the referring physician, ...
... Journal of Traumatic Stress finds that for ... happily married, communicating frequently with one,s spouse through letters ... of posttraumatic stress disorder (PTSD) symptoms after returning home. ... soldiers who returned from military deployment within the past ...
... By Amanda Gardner HealthDay Reporter , THURSDAY, ... dangerous strain of E. coli bacteria in Europe ... experts say. "Bacteria are constantly mutating and changing. They,re ... different," said Dr. Bruce Hirsch, an attending physician in infectious ...
... 10-page letter addressed to Donald Berwick, administrator of the ... The ACP strongly supports the intent of the ... potential of supporting such important care delivery goals as ... pleased that,the foundation of care under this payment model, ...
Cached Medicine News:Health News:Benefit of targeted lung cancer therapy confirmed 2Health News:Paper and computer workarounds challenge but may improve health IT 2Health News:Paper and computer workarounds challenge but may improve health IT 3Health News:Letters from home may help prevent post-traumatic stress disorder in happily married soldiers 2Health News:Deadly E. Coli Strain in Europe Should Serve as Warning, Experts Say 2Health News:Deadly E. Coli Strain in Europe Should Serve as Warning, Experts Say 3Health News:Supportive of intent of ACO proposed rule, ACP expresses concern 2Health News:Supportive of intent of ACO proposed rule, ACP expresses concern 3
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
The AMY method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of amylase activity in serum, plasma and urine....
For the quantitative in vitro determination of Aspartate Aminotransferase (AST) in serum and plasma....
This is an Immunological assay intended for the quantitative in vitro determination of haemoglobin A1c (HbA1c) in whole blood....
Medicine Products: